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Abstract: Objective: This review examines the use of exenatide twice daily in managing changes
in markers of cardiovascular risk in patients with type 2 diabetes. Background: Type 2 diabetes is
a progressive metabolic disorder, which results from defects in insulin secretion and/or insulin
action leading to chronic hyperglycaemia and associated cardiovascular complications. Despite the
use of diet, exercise, oral antihyperglycaemic agents and insulin, the progressive nature of the
condition means that the levels of the preventive and treatment measures would have to be increased
and/or new therapies have to be developed in order to address the long term impact of type 2
diabetes. The advent of exenatide, a glucagon-like peptide-1 receptor agonist provides a useful
basis for managing type 2 diabetes and related cardiovascular complications without the side effects
of regular diabetes therapies. However, exenatide twice daily is often used in combination with
other therapies, although the mechanism of exenatide in managing diabetes and and associated
cardiovascular risks and complications remain complex and still evolving. Method: A range of
databases including EBSCOhost online research database were used to access articles based on PICO
(Population, Interventions, Comparative Interventions, Outcomes) framework and Boolean operators.
Results: Eleven randomised controlled studies which met the inclusion criteria were selected for this
review. Nine of the eleven studies showed significant decrease in body weight among participants
in the exenatide group compared with placebo or control group while the other two studies did
not report statistically significant differences in body weight. In adition, all the studies showed
statistically significant decrease in glycated haemoglobin (HbA1c) in the exenatide group compared
to controls except in one study. In the present review, the seven studies, which looked at the effect of
exenatide twice daily on lipid profile, did not find any significant difference between the exenatide
group and the control group except for High density lipoprotein-cholesterol in two of the studies.
However, statistically significant decrease was observed between exenatide group and controls with
respect to blood pressure (systolic and/or diastolic) in these studies. Discussion: It would appear
that exenatide is more effective in reducing body weight in patients with type 2 diabetes when used
in combination with metformin than when used alone or in combination with thiazolidinedione.
The findings of this review would suggest that exenatide twice daily may be useful in managing
cardiovascular risks and complications by reducing body weight, HbA1c and blood pressure.
Keywords: exenatide; type 2 diabetes; cardiovascular risk; glycated haemoglobin; glycaemic
control; metformin
1. Introduction
Type 2 diabetes is a progressive metabolic disorder of multiple aetiology resulting from defects in
insulin secretion from the beta cells and/or insulin resistance in peripheral tissues leading to chronic
hyperglycaemia [1].
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Patients with type 2 diabetes are at greater risk of developing cardiovascular disease (CVD).
According to Saraiva and Sposito [2], about 68% of people over 65 years of age with diabetes die of
some form of cardiovascualr disease and CVD deaths amongst adults with diabetes are two to four
times higher than those without diabetes. Although some observational studies have demonstrated
that a higher glycated haemoglobin (HbA1c) level was associated with increased risks of cardiovascular
diseases and deaths, the underlying mechanisms remain complex [3,4].
The progressive nature of type 2 diabetes despite the use of diet, physical activity and current
therapies, such as metformin, sulfonylurea and insulin, may explain why therapeutic requirements
tend to increase with time [1,5]. Therefore, other strategies have to be developed in order to
control the resulting hyperglycaemia and associated complications although researchers continue to
debate which combination therapies will be effective in controlling hyperglycamia [5]. For example,
Jansson et al. [6] demonstrated the protective effect of low-cost diabetes drugs on the negative
influences of hyperglycaemia regarding all cardiovascular diseases combined and myocardial
infarction. The addition of sulfonylurea and thiazolidinedione as treatment for diabetes are useful
alternatives, however, these may have their limitations including the problems of hypoglycaemia, their
tendency to elicit weight gain and oedema with potential to reduce patient compliance [1,5]. Therefore,
new therapies, which do not have the usual side effects of the current therapies, have to be developed.
The National Institute for Health and Care Excellence (NICE) guideline [7] in the UK clearly
outlined the algorithm for blood glucose lowering therapy in adults with type 2 diabetes. According to
the guideline, if a triple therapy (such as metformin, a Dipeptidyl peptidase-4-inhibitor and
sulfonylurea) is not effective, not tolerated or contraindicated, then, it will be useful to consider
combination therapy with metformin, a sulfonylurea and a Glucagon-like peptide-1 (GLP-1) mimetic
for adults with type 2 diabetes. To qualify for this treatment, the patients should have body mass
index (BMI) of ≥ 35 kg/m2 or have a lower BMI than 35 kg/m2 and for whom insulin therapy would
have significant occupational implications, or weight loss would benefit other significant obesity
related co-morbidities. Similar approach in the form of algorithm for the initiation and adjustment of
therapy in the management of hyperglycaemia in patients with type 2 diabetes has been developed [8].
This framework is based on consensus between the American Diabetes Association and the European
Association for the Study of Diabetes [8].
The advent of the use of GLP-1 based therapies has brought new dimension in the management
of type 2 diabetes and associated cardiovascular complications. According to McCormack [9], human
GLP-1 is produced by L-cells of the intestinal mucosa and is an incretin, a gastrointestinal hormone
responsible for the enhanced secretion of insulin from the beta cells of the pancreas in response to
food intake. In addition, GLP-1 receptor agonists, such as exenatide, significantly decrease glycated
haemoglobin through suppressing glucagon production, delaying gastric emptying, and reducing
appetite and food intake by increasing satiety [10].
Exenatide is a 39-amino acid peptide and is an incretin mimetic, which was the first of the new
incretin mimetic class of antihyperglycaemic agents to be marketed in the US and European Union [9,11].
Exenatide is a short acting agent, which can be administered subcutaneously twice daily (exenatide
BID) although the extended release formulation can be administered once weekly (exenatid QW) [9].
There is evidence that exenatide has some advantages over current therapies for patients with
type 2 diabetes. It does decrease the risk of severe hypoglycaemia when used in the absence of insulin
or sulfonylurea and it is associated with reductions in body weight in the absence of diet and exercise
programme [11,12]. It has been reported that GLP-1 can stimulate the proliferation and neogenesis of
beta cells and may also inhibit their apoptosis [13]. In addition, GLP-1 decreases gastrointestinal motility,
which could extend the entry of nutrients to be absorbed by the gastrointestinal tract and thus controls
postprandial glucose levels and ensure normal glucose homeostatis [2]. Impairment in the secretion of
GLP-1 has been considered in the pathophysiology of type 2 diabetes and the administration of GLP-1
receptor agonists, which restores GLP-1 function has been shown to promote insulin secretion, sensitivity
and enhance long term prognosis including reduction in cardiovascular risks and complications [14].
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In patients with type 2 diabetes, the incretin effect is significantly impaired due to reduced
production of GLP-1, metablolism and/or impairment of their actions [13]. The incretin effect has been
defined as the difference in insulin secretion from an oral gluscose load compared with intravenous
glucose administration and results from the observation that intrajejunal glucose enhances greater
insulin release than intravenous glucose administration [2,15].
In view of the above, this is a systematic review of randomised controlled studies aimed at
evaluating the potential role of exenatide and combination treatments on physiological and biochemical
markers of cardiovascular risk in patients with type 2 diabetes. The objective of this review is to
examine the use of exenatide twice daily in managing changes in markers of cardiovascular risk in
patients with type 2 diabetes.
2. Methods
This review involved a literature search including a general scoping of the data bases which
found previous reviews relevant to the population and intervention of interest, but these were either
more than 5 years old, were narrative reviews or included other GLP-1 agonists, such as liraglutide,
and/or included studies which were not randomised. The current systematic review is based only on
randomised controlled studies.
The literature search strategy for this review relied on previously published guidelines for
reviews [16,17] and was based on the PICO framework; P (Population—patients with type 2 diabetes),
I (Interventions—exenatide twice daily), C (Comparative interventions—control group, placebo) and
O (Outcomes—Glycaemic control, glycated haemoglobin, microvascular complications, macrovascular
complications, cardiovascular complications). A number of databases including EBSCOhost online
research database, encompassing Academic search premier, Medline, Psychology and Behavioural
sciences collection, PsycINFO®, SPORTDiscuss and Cumulative Index to Nursing and Allied Health
Literature (CINAHL) Plus were accessed.
In addition, “Boolean” operators (and/or) allowing the combination of search terms and
alternative search terms were used; “exenatide“ and “diabetes“ and “cardiovascular diseases“;
“exenatide“ and “diabetes“ and “glycaemic control“; “GLP-1“ and “diabetes“; “GLP-1“ and “diabetes“
and “cardiovascular diseases“; “GLP-1“ and “diabetes“ and “macrovascular diseases“; “exenatide“ and
“cardiovascular risks“; “exenatide“ and “cardiovascular complications“; “exenatide“ and “glycaemic
control“; “exenatide“ and “diabetes“ or “glycaemic control“; “exenatide“ and “diabetes“ or “GLP-1“.
References of articles were also reviewed to search for relevant studies.
2.1. Inclusion Criteria
Studies included were those written in English and published between 2010 and 2016 only.
In addition, only randomised controlled studies were selected for review.
2.2. Exclusion Criteria
Studies which did not meet the inclusion criteria outlined above were excluded from the review.
The original hits were filtered and narrowed down using the above criteria.
2.3. Quality Assurance
The evaluation process involved assessing the quality of the research articles and this was based
on the Scottish Intercollegiate Guidelines Network (SIGN) checklist for critical appraisal [18] and
expert review of the articles.
Int. J. Environ. Res. Public Health 2016, 13, 941 4 of 11
Table 1. Summary of studies.
Citation Country Length ofStudy Study Type
Sample
Size
Age
(Years)
Diabetes
Duration
(Years)
Background
Treatment Intervention Glycaemic Control Lipid Profile
Blood Pressure and
Heart Rate
Outcomes/Body
Weight
Gastaldelli
et al. [19]
4 countries
(Multi-centre) 24 weeks
Randomised
Controlled
Study
79
Exenatide
(10 µg)
59 ± 2
2 ± 3
(exenatide
5 µg)
–
Exenatide
twice
daily
versus
placebo
Compared to placebo, 24 weeks
of daily high or low dose
exenatide treatment significantly
reduced HbA1c (p < 0.01) and
fasting plasma glucose (p < 0.05)
– –
There were no
differences in weight
changes between the
two exenatide and
placebo groups
Exenatide
(5 µg)
57 ± 2
2 ± 3
(exenatide
10 µg)
Placebo
54 ± 2
1 ± 2
(placebo)
Derosa
et al. [20]
Italy
(Multi-centre) 4 years
Randomised
Controlled
Study
174 57.1 ± 7.6 7.8 ± 3.2
Metformin (given for
8 months before
randomly assigning
patients), diet and
exercise advise
(commenced at
baseline)
Exenatide
twice
daily
versus
placebo
Exenatide + metformin were
better than placebo + metformin
in decreasing HbA1c at
12 months (p < 0.05). Similar
trend was recorded for fasting
blood glucose.
No variation in
lipd profile were
observed in either
of the 2 groups
Systolic and diastolic
BP were not changed
by placebo +
metformin, but
decreased by
treatment with
exenatide +
metformin at 12
months compared
with point of
randomisation
(p < 0.05)
Body mass and BMI
obtained after
9 months and
12 months of
exenatide +
metformin were
lower than the ones
obtained for placebo
+ metformin group
(p < 0.05 and p < 0.01
respectively)
Rosenstock
et al. [21]
5 countries
(Multi-centre) 30 weeks
Randomised
Controlled
Study
259
59 ± 9
(exenatide)
12 ± 7
(Exenatide)
Insulin glargine,
metformin,
pioglitazone
Treatments given to
participants for at
least 3 months before
study commenced
and continued
throughout study
period.
Exenatide
twice
daily
versus
placebo
Exenatide participants had
greater HbA1C reductions
compared with placebo
participants at end point
(p < 0.001)
– –
Exenatide
participants lost
more weight
(p < 0.05)
59 ± 10
(placebo)
12 ± 7
(placebo)
Buse et al.
[22]
5 countries
(59 centres) 30 weeks
Randomised
Controlled
Study m
259
59 ± 9
(exenatide)
12 ± 7
(exenatide)
Insulin glargine with
or without
metformin or
pioglitazone (or both
agents). Treatments
given to participants
for at least 3 months
before study
commenced and
continued
throughout study
period.
Exenatide
twice
daily
versus
placebo
HbA1c level decreased by 1.74%
with exenatide and 1.04% with
placebo (p < 0.001). Proportion
of participants who had minor
hypoglycaemia were similar in
both groups
Concentration of
triglycerides,
LDL, HDL did
not differ
between the
groups
Systolic and diastolic
pressures decreased
(p < 0.01 and
p < 0.001)
respectively from
basline with
exenatide. Heart rate
increased from
baseline in the
exenatide group
Weight decreased by
1.8 kg with exenatide
and increased by
1.0 kg with placebo59 ± 10
(placebo)
12 ± 7
(placebo)
Int. J. Environ. Res. Public Health 2016, 13, 941 5 of 11
Table 1. Cont.
Citation Country Length ofStudy Study Type
Sample
Size
Age
(Years)
Diabetes
Duration
(Years)
Background
Treatment Intervention Glycaemic Control Lipid Profile
Blood Pressure and
Heart Rate
Outcomes/Body
Weight
Gill et al.
[23]
Canada and
Netherlands
(Multi-centre)
12 weeks
Randomised
Controlled
Study
54
Exenatide
57 ± 11
7 ± 4
(exenatide)
Metformin (given for
30 days and
continued
during study),
thiazolidinedione
(given for 120 days
and continued
during study),
metformin +
thiazolidinedione
(continued
during study).
Exenatide
twice
daily
versus
placebo
HbA1c reduction was not
significantly different between
the 2 groups (p = 0.26)
–
Differences in heart
rate between the 2
groups was not
significant (p = 0.16).
Exenatide therapy
showed trends
towards lower
systolic BP, but
similar diastolic BP
between the groups.
There were
significant
differences (p < 0.05)
in body weight
between exenatide
and placebo group.
Placebo
54 ± 10
6 ± 4
(placebo)
Kadowaki
et al. [24]
Japan
(23 centres) 24 weeks
Randomised
Controlled
Study
179 58 ± 10
12.2 ± 6.3
(exenatide
5 µg)
Sulfonylurea,
Sulfonylurea and
biguanide,
sulfonylurea and
thiazolidine
derivative.
Treatments given to
participants for
90 days before
screening.
Exenatide
twice
daily
versus
placebo
The changes in HbA1c levels
were significantly greater
(p < 0.001) in both exenatide
groups than the placebo group.
The reduction in
HDL cholesterol
was statistically
greater in both
exenatide groups
(5 µg, p = 0.020
and 10 µg
p = 0.014) than
placebo group.
No statistically
significant
differences were
observed in total
cholesterol, LDL
cholesterol and
triglycerides
–
Reduction in body
weight were
significantly greater
(p = 0.026) in
exenatide 10 µg
group, than placebo
group.
11.6 ± 7.0
(exenatide
10 µg)
12.4 ± 6.5
(placebo)
Liutkus
et al. [25]
5 countries
(Multi-centre) 26 weeks
Randomised
Controlled
Study
165
Exenatide
(55 ± 8)
Exenatide
(6.3 ± 4.2)
Thiazolidinedione
(given for 120 days
before study),
metformin +
thiazolidinedione
(given for at least 90
days before study).
Participants
continued their usual
treatment for the
duration of study.
Exenatide
twice
daily
versus
placebo
Exenatide showed superiority
with respect to change in HbA1c
(p < 0.001) and fasting serum
glucose (p = 0.009) compared
with placebo
There were no
significant
changes in fasting
serum lipids
between
treatment groups.
Diastolic pressure
was significantly
reduced in both
treatment groups,
while systolic BP
remained relatively
unchanged from
baseline values.
Mean reductions in
body weight were
not significantly
different between
treatments at
endpoint
Placebo
(54 ± 9)
Placebo
(6.4 ± 4.6)
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Table 1. Cont.
Citation Country Length ofStudy Study Type
Sample
Size
Age
(Years)
Diabetes
Duration
(Years)
Background
Treatment Intervention Glycaemic Control Lipid Profile
Blood Pressure and
Heart Rate
Outcomes/Body
Weight
Apovian
et al. [26]
USA (11
centres) 24 weeks
Randomised
Controlled
Study
194 54.8 ± 9.5
Exenatide
(5.7 ± 5.5)
Metformin or
sulfonylurea or both.
Participants treated
for at least 6 weeks
before study and
continued during
study.
Exenatide
twice
daily +
lifestyle
modification
programme
placebo +
lifestyle
modification
programme
Significantly more participants
treated with exenatide + lifestyle
modification had HbA1c ≤ 6.5%
at end point compared with
placebo + lifestyle modification
(p = 0.001)
–
Exenatide + lifestyle
modification was
associated with
significant decrease
in systolic and
diastolic BP at
24 weeks from
baseline compared
with placebo +
lifestyle modification
(p < 0.001; p = 0.04 )
Exenatide + lifestyle
modification had
significantly more
weight loss
compared with
placebo + lifestyle
modification
(p < 0.01)
Placebo
(5.3 ± 5.1)
Simo et al.
[27]
14 countries
(Multi-centre)
41/2 years
Randomised
Controlled
Study
Exenatide
(n = 511)
18–85
5.8 ± 4.8
(exenatide)
Metformin
(participants treated
before study and
continued treatment
during study)
Exenatide
twice
daily
versus
glimepiride
Symptomatic hypoglycaemia
was reported during 1 year of
study treatment by 13.5%
(exenatide group) and 39.0%
(glimepiride group) (p < 0.0001)
A significantly
greater
proportion of
exenatide treated
patients
achieved the
HDL-cholesterol
goal than
glimepiride
treated patients at
36 months
(p = 0.021)
Between-group
differences were
significantly in favor
of exenatide for
systolic BP
(p < 0.001), diastolic
BP (p = 0.023)
Between-group
differences were
significantly in favor
of exenatide for body
weight (p < 0.0001),
waist circumference
(p < 0.001).
Glimepiride
(n = 508)
5.5 ± 4.3
(glimepiride)
Gallwitz
et al. [28]
14 countries
(128 centres)
41/2 years
Randomised
Controlled
Study
Exenatide
= 490
18–85
5.8 ± 4.8
(exenatide)
Metformin
(participants treated
before study and
continued treatment
during study)
Exenatide
twice
daily
versus
glimepiride
44% in exe natide group and
31% in glimepiride gp achieved
HbA1c < 7% (p < 0.0001). 29% in
exenatide gp and 18% in
glimepiride group achieved
HbA1c ≤ 6.5% (p = 0.0001).
Significantly fewer patients
reported hypoglycaemia in
exenatide group compared with
glimepiride group (p < 0.0001)
–
Systolic pressure
decreased
significantly in the
exenatide group
(p = 0.006) but not in
the glimepiride
group (p = 0.096).
Heart rate increased
in the exenatide
group.
Significant decrease
(p < 0.0001) in body
weight in exenatide
group compared
with glimepiride
group
Glimepiride
= 487
5.5 ± 4.3
(glimepiride)
Gallwitz
et al. [29]
Germany
(Multi-centre) 26 weeks
Randomised
Controlled
Study
354
57 ± 10
(Exenatide)
5 ± 4
(Exenatide)
Metformin
(participants treated
before study and
continued treatment
during study)
Exenatide
twice
daily
versus
premixed
insulin
aspart
(PIA)
HbA1c targets < 7% and <6.5%
(exenatide noninferior to PIA).
Hypoglcaemic epiosdes with
blood glucose ≤ 3.0 mmols/L
were less frequent with
exenatide BID
– –
Exenatide twice daily
(weight loss =
4.1 ± 0.22 kg)
PIA
(weight gain =
1.0 ± 0.22 kg) SEM
(p < 0.001)
57 ± 9.9
(PIA)
5 ± 5
(PIA)
HbA1c = Glycated haemoglobin; BP = Blood pressure; BMI = Body mass index; HDL = High density lipoprotein; LDL = Low density lipoprotein; PIA = Premixed insulin aspart;
SEM = Standard error of mean.
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2.4. Data Analysis
On the basis of the inclusion and exclusion criteria, 19,065 articles including full articles and
abstracts were initially found following a search of the databases. However, based on the use of various
search terms, this was significantly narrowed to smaller numbers. Of these, 11 articles which met the
requirements for selection were included in the review (Table 1).
3. Results
All the eleven studies [19–29] (Table 1) for this review were multicentre and randomised controlled
studies involving patients with type 2 diabetes. While seven of the studies [19,21–23,25,27,28] were
conducted in at least 2 countries, the remaining 4 [20,24,26,29] were conducted in Italy, Japan, the
US and Germany respectively. However, all eleven studies had background treatment in addition
to the intervention treatments except the study by Gastaldelli et al. [19]. The background treatments
included metformin and/or insulin glargine, pioglitazone, diet and exercise, and thiazolidinedione.
Other background treatments were sulfonylurea and/or biguanide, thiazolidinedione and/or metformin.
The background treatments were treatments taken by participants before the commencement of the
study and/or during study (Table 1).
The sample size of the studies ranged from 54 to 1019 while the length of study ranged from
12 weeks to 41/2 years. The duration of diabetes of the patients in the studies ranged from 1 ± 2 to
12 ± 7 years (Mean ± SD).
3.1. Exenatide Twice Daily versus Placebo
Exenatide twice daily was compared to placebo in seven of the 11 studies [19–25] (Table 1).
Participants in the exenatide groups with metformin as one of the background treatments showed
statistically significant decrease in body weight in five of the studies [20–24] compared to placebo
group. However, mean reductions in body weight were not statistically significant between exenatide
and placebo groups in the studies by Gastaldelli et al. [19] and Liutkus et al. [25].
In addition, the exenatide group in all the seven studies showed statistically significant decrease
in HbA1c compared with the placebo group except for one study [23], where HbA1c reduction was
not significantly different between the two groups (p = 0.26).
There were no significant differences in lipid profile between the exenatide groups and the
placebo group [20,22,24,25] except with respect to HDL cholesterol in the study by Kadowaki et al. [24].
That study showed that significant reduction in HDL cholesterol was statistically greater in both
exenatide groups compared to placebo although no statistically significant difference was observed
in total cholesterol, LDL-cholesterol and triglycerides. However, systolic and diastolic BP decreased
significantly in the exenatide group compared to placebo group in two studies [20,22]. In another
study [25], diastolic pressure was significantly reduced in both treatment groups, while systolic blood
pressure remained relatively unchanged from baseline values.
3.2. Exenatide Twice Daily versus Other Controls
While one of the remaining 4 studies had placebo + lifestyle modification as control [26], the
other 3 studies were not placebo controlled [27–29]. The interventions included; exenatide + lifestyle
modification versus placebo + lifestyle modification with metformin and/or sulfonylurea as background
treatment [25]; exenatide versus Glimepiride with metformin as background treatment [27,28]; exenatide
versus premixd insulin aspart with metformin as background treatment [29].
In all the 4 studies [26–29] (Table 1), there were significantly better clinical outcomes in
the exenatide groups compared with glimepiride, premixed insulin aspart, placebo plus lifestyle
modification programme, based on the specific outcomes measured by each study (body weight, blood
pressure, lipid profile and glycaemic control). For example, there was significant decrease in body
weight in exenatide group compared to control groups in all the four studies.
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With respect to HbA1c targets (<7% and <6.5%) exenatide twice daily was non inferior compared
to premixed insulin aspart [29]. In addition, there were significant differences in favour of the
exenatide groups compared with the glimepiride group with respect to HbA1c < 7% (p < 0.0001)
and HbA1c < 6.5% (p = 0.0001) [28]. The percentage of hypoglycaemia in the exenatide group
was significantly (p < 0.0001) lower than the glimepiride group [27,28]. When compared with the
placebo plus lifestyle, the exenatide plus lifestyle groups had significantly more participants who had
HbA1c ≤ 6.5% (p = 0.001) [26].
The study by Simo et al. [27] showed that a statistically significant proportion of exenatide treated
patients achieved the HDL-cholesterol goal than glimepiride treated patients at 36 months (p = 0.021).
In addition, systolic blood pressure (BP) [26–28] and diastolic BP [26,27] decreased significantly in the
exenatide groups compared with controls.
4. Discussion
The exact mechanisms of the potential benefit of exenatide in the control of cardiovascular risks
and complications are complex and still evolving [12,13]. However, the findings of this review would
suggest that the influence of exenatide in possibly managing cardiovascular risks and complications
may be through its effect in reducing glycated haemoglobin (HbA1c), reducing body weight and blood
pressure. These are the markers of cardiovascular risk [27]. This view is supported by previous reports,
which revealed that the probable effects of exenatide may be through glycaemic control based on
the link between HbA1c and cardiovascular events and evidence that tight glycaemic control and/or
decrease in HbA1c has been shown to reduce microvascular risks and complications [1,9,12].
High levels of glycated haemoglobin have been proposed as independent risk factors for patients
with diabetes and those without diabetes [30]. In addition, higher HbA1c levels are known to be
positively correlated with future risk of stroke and coronary heart disease, and that for every 1%
rise in HbA1c, there is an associated 8% increased risk of first cardiovascular event [3,31]. In the
present review, all the studies showed statistically significant decrease in HbA1c in the exenatide
group compared to controls except in the study by Gill et al. [23]. Perhaps the sample size with only
54 participants in the Gill et al. [23] study was not large enough to elicit any statistically significant
difference in the HbA1c level compared to the other studies with sample sizes ranging from 79 to 1019
participants. The Simo et al. [27] study had no report on HbA1c levels.
Another possible mechanism of the likely benefit of exenatide on cardiovascular risks and
complications is its impact on body weight. Based on the results of the studies reviewed, it is
clear that nine of the eleven studies showed significant decrease in body weight among participants
in the exenatide group compared with placebo or control group. Only two studies [19,25] did
not report statistically significant differences in body weight between exenatide group and control
group. While one of these studies had no background treatment [19], the other had thiazolidinedione,
metformin plus thiazolidinedione [25]. Therefore, it would appear that exenatide is more effective in
reducing body weight in patients with type 2 diabetes when used in combination with metformin than
when used alone or in combination with thiazolidinedione. Increases in body weight and body mass
index in patients with type 2 diabetes have been reported to increase the risk of cardiovascualr diseases
whereas reduction in body weight increases insulin sensitivity and reduces blood pressure [12,32].
In addition, exenatide twice daily is superior to insulin, sulfonylureas and rosiglitazone in decreasing
body weight [9].
Another mechanism of the potential action of exenatide on cardiovascular risks and complications
may be its effect on the pathogenic link between type 2 diabetes and atherosclerosis [13]. The formation
of advanced glycation endproducts (AGE) in patients with type 2 diabetes plays a key role in vascular
damage and exenatide has been reported to ameliorate this deleterious effects of AGEs [13].
According to Anagnostis et al. [13], the main mechanism of the antihypertensive role of exenatide
may be due to its effect on weight loss although the authors also alluded to the vasodilatory effects
of GLP-1. Although exenatide twice daily may improve blood pressure and certain lipid parameters,
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changes are often small and variable between studies [9,33]. In the present review, the studies, which
looked at the effect of exenatide twice daily on lipid profile [20,22,24–28], did not find any significant
difference between the exenatide group and the control group except for HDL-cholesterol [24,27].
However, statistically significant decrease was observed between exenatide group and controls with
respect to blood pressure (systolic and/or diastolic) in these studies.
With respect to glycaemic control, episodes of hypoglycaemia were less frequent in the exenatide
group compared to glimepiride [27,28] and premixed basal insulin aspart [29] groups. This appears to
be in tandem with previous reports which suggest that the incidence of hypoglycaemia is relatively
low with exenatide treatment except when used in combination with a sulfonylurea due to their
mechanism of action, which is glucose dependent [15].
5. Conclusions
Based on the findings of this review, it would appear that exenatide twice daily may be useful
in managing cardiovascular risks and complications by reducing body weight, HbA1c and blood
pressure. In particular, the combination of exenatide with metformin was more effective in reducing
body weight than using exenatide alone.
Conflicts of Interest: The author declares no conflict of interest.
References
1. DeFronzo, R.A.; Ratner, R.E.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4)
on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Diabetes Care 2005, 28, 1092–1100. [CrossRef] [PubMed]
2. Saraiva, F.; Sposito, A. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists.
Cardiovasc. Diabetol. 2014, 13, 1–21. [CrossRef] [PubMed]
3. Chen, Y.Y.; Lin, Y.J.; Chong, E.; Chen, P.C.; Chao, T.F.; Chen, S.A.; Chien, K.L. The impact of diabetes mellitus
and corresponding hba1c levels on the future risks of cardiovascular disease and mortality: A representative
cohort study in Taiwan. PLoS ONE 2015, 10, 1–12. [CrossRef] [PubMed]
4. Naka, K.K.; Papathanassiou, K.; Bechlioulis, A.; Kazakos, N.; Pappas, K.; Tigas, S.; Makriyiannis, D.;
Tsatsoulis, A.; Michalis, L.K. Determinants of vascular function in patients with type 2 diabetes.
Cardiovasc. Diabetol. 2012, 11, 127. [CrossRef] [PubMed]
5. Kendall, D.M.; Riddle, M.C.; Rosenstock, J.; Zhuang, D.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of
exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with
metformin and a sulfonylurea. Diabetes Care 2005, 28, 1083–1091. [CrossRef] [PubMed]
6. Jansson, S.P.; Svärdsudd, K.; Andersson, D.K. Effects of fasting blood glucose levels and blood pressure and
treatment of diabetes and hypertension on the incidence of cardiovascular disease: A study of 740 patients
with incident type 2 diabetes with up to 30 years’ follow-up. Diabet. Med. 2014, 31, 1055–1063. [CrossRef]
[PubMed]
7. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management; NICE Posted
December 2, 2015. Available online: https://www.nice.org.uk/guidance/ng28 (accessed on 14 June 2016).
8. Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Ferrannini, E.; Holman, R.R.; Sherwin, R.; Zinman, B.
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and
adjustment of therapy. Diabetes Care 2009, 32, 193–203. [CrossRef] [PubMed]
9. McCormack, P. Exenatide twice daily: A review of its use in the management of patients with type
2 diabetes mellitus. Drugs 2014, 74, 325–351. [CrossRef] [PubMed]
10. Ferdinand, K.C.; Botros, F.T.; Atisso, C.M.; Sager, P.T. Cardiovascular safety for once-weekly dulaglutide
in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Cardiovasc. Diabetol. 2016, 15, 1–12. [CrossRef] [PubMed]
11. Ratner, R.E.; Maggs, D.; Nielsen, L.L.; Stonehouse, A.H.; Poon, T.; Zhang, B.; Bicsak, T.A.; Brodows, R.G.;
Kim, D.D. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in
over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2006, 8, 419–428.
[CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2016, 13, 941 10 of 11
12. Ratner, R.; Han, J.; Nicewarner, D.; Yushmanova, I.; Hoogwerf, B.J.; Shen, L. Cardiovascular safety of
exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes.
Cardiovasc. Diabetol. 2011, 10, 22. [CrossRef] [PubMed]
13. Anagnostis, P.; Athyros, V.G.; Adamidou, F.; Panagiotou, A.; Kita, M.; Karagiannis, A.; Mikhailidis, D.P.
Glucagon-like peptide-1-based therapies and cardiovascular disease: Looking beyond glycaemic control.
Diabetes Obes. Metab. 2011, 13, 302–312. [CrossRef] [PubMed]
14. Saraceni, C.; Broderick, T. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular
and metabolic function. Drugs R&D 2007, 8, 145–153.
15. Garber, A.J. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability.
Diabetes Care 2011, 34 (Suppl. 2), S279–S284. [CrossRef] [PubMed]
16. Bettany-Saltikov, J. How to Do a Systematic Literature Review in Nursing; Ashford Colour Press Ltd.: Gosport,
Hampshire, UK, 2012.
17. Wright, R.W.; Brand, R.A.; Dunn, W.; Spindler, K.P. How to write a systematic review. Clin. Orthop. Relat. Res.
2007, 455, 23–29. [CrossRef] [PubMed]
18. Scottish Intercollegiate Guidelines Network (SIGN). Critical Appraisal: Notes and Checklists.
Available online: http://www.sign.ac.uk/methodology/checklists.html (accessed on 3 November 2015).
19. Gastaldelli, A.; Brodows, R.; D’Alessio, D. The effect of chronic twice daily exenatide treatment on β-cell
function in new onset type 2 diabetes. Clin. Endocrinol. 2014, 80, 545–553. [CrossRef] [PubMed]
20. Derosa, G.; Cicero, A.; Franzetti, I.; Querci, F.; Carbone, A.; Ciccarelli, L.; D’Angelo, A.; Fogari, E.; Maffioli, P.
Effects of exenatide and metformin in combination on some adipocytokine levels: A comparison with
metformin monotherapy. Can. J. Phys. Pharmacol. 2013, 91, 724–732. [CrossRef] [PubMed]
21. Rosenstock, J.; Shenouda, S.; Bergenstal, R.; Buse, J.; Glass, L.; Heilmann, C.; Kwan, A.; MacConell, L.;
Hoogwerf, B. Baseline factors associated with glycemic control and weight loss when exenatide twice daily
is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012, 35, 955–958.
[CrossRef] [PubMed]
22. Buse, J.B.; Bergenstal, R.M.; Glass, L.C.; Heilmann, C.R.; Lewis, M.S.; Kwan, A.Y.; Hoogwerf, B.J.;
Rosenstock, J. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes:
A randomized, controlled trial. Ann. Intern. Med. 2011, 154, 103–112. [CrossRef] [PubMed]
23. Gill, A.; Hoogwerf, B.J.; Burger, J.; Bruce, S.; MacConell, L.; Yan, P.; Braun, D.; Giaconia, J.; Malone, J.
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind,
placebo-controlled, randomized pilot study. Cardiovasc. Diabetol. 2010, 9, 1–7. [CrossRef] [PubMed]
24. Kadowaki, T.; Namba, M.; Imaoka, T.; Yamamura, A.; Goto, W.; Boardman, M.K.; Sowa, H. Improved glycemic
control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese
patients with suboptimally controlled type 2 diabetes over 24 weeks. J. Diabetes Investig. 2011, 2, 210–217.
[CrossRef] [PubMed]
25. Liutkus, J.; Rosas Guzman, J.; Norwood, P.; Pop, L.; Northrup, J.; Cao, D.; Trautmann, M. A placebo-controlled
trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
Diabetes Obes. Metab. 2010, 12, 1058–1065. [CrossRef] [PubMed]
26. Apovian, C.M.; Bergenstal, R.M.; Cuddihy, R.M.; Qu, Y.; Lenox, S.; Lewis, M.S.; Glass, L.C. Effects of
exenatide combined with lifestyle modification in patients with type 2 diabetes. Am. J. Med. 2010. [CrossRef]
[PubMed]
27. Simó, R.; Guerci, B.; Schernthaner, G.; Gallwitz, B.; Rosas-Guzmàn, J.; Dotta, F.; Festa, A.; Zhou, M.;
Kiljan´ski, J. Long-term changes in cardiovascular risk markers during administration of exenatide twice
daily or glimepiride: Results from the European exenatide study. Cardiovasc. Diabetol. 2015, 14, 1–13.
[CrossRef] [PubMed]
28. Gallwitz, B.; Guzman, J.; Dotta, F.; Guerci, B.; Simó, R.; Basson, B.R.; Festa, A.; Kiljan´ski, J.; Sapin, H.;
Trautmann, M.; et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in
patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial.
Lancet 2012, 379, 2270–2278. [CrossRef]
29. Gallwitz, B.; Böhmer, M.; Segiet, T.; Mölle, A.; Milek, K.; Becker, B.; Helsberg, K.; Petto, H.; Peters, N.;
Bachmann, O. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients
with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care
2011, 34, 604–606. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2016, 13, 941 11 of 11
30. Eskesen, K.; Jensen, M.T.; Galatius, S.; Vestergaard, H.; Hildebrandt, P.; Marott, J.L.; Jensen, J.S.
Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the
Copenhagen City Heart Study. J. Intern. Med. 2013, 273, 94–101. [CrossRef] [PubMed]
31. Elley, C.R.; Kenealy, T.; Robinson, E.; Drury, P.L. Glycated haemoglobin and cardiovascular outcomes in
people with type 2 diabetes: A large prospective cohort study. Diabet. Med. 2008, 25, 1295–1301. [CrossRef]
[PubMed]
32. Seimon, R.V.; Espinoza, D.; Ivers, L.; Gebski, V.; Finer, N.; Legler, U.F.; Sharma, A.M.; James, W.P.;
Coutinho, W.; Caterson, I.D. Changes in body weight and blood pressure: Paradoxical outcome events in
overweight and obese subjects with cardiovascular disease. Int. J. Obes. 2014, 38, 1165–1171. [CrossRef] [PubMed]
33. Blonde, L.; Klein, E.J.; Han, J.; Zhang, B.; Mac, S.M.; Poon, T.H.; Taylor, K.L.; Trautmann, M.E.; Kim, D.D.;
Kendall, D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk
factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 2006, 8, 436–447.
[CrossRef] [PubMed]
© 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
